A new trading day began on Friday, with Beam Therapeutics Inc (NASDAQ: BEAM) stock price up 9.34% from the previous day of trading, before settling in for the closing price of $24.52. BEAM’s price has ranged from $16.95 to $49.50 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 43297.50% over the past five years. Meanwhile, its annual earnings per share averaged -173.05%. With a float of $71.58 million, this company’s outstanding shares have now reached $81.63 million.
Let’s look at the performance matrix of the company that is accounted for 436 employees. In terms of profitability, gross margin is 93.24%, operating margin of -52.31%, and the pretax margin is -40.16%.
Beam Therapeutics Inc (BEAM) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Beam Therapeutics Inc is 13.15%, while institutional ownership is 81.49%. The most recent insider transaction that took place on Jul 02 ’24, was worth 17,167. In this transaction Chief Medical Officer of this company sold 748 shares at a rate of $22.95, taking the stock ownership to the 68,805 shares. Before that another transaction happened on Jul 01 ’24, when Company’s Chief Medical Officer sold 502 for $23.76, making the entire transaction worth $11,928. This insider now owns 69,553 shares in total.
Beam Therapeutics Inc (BEAM) Latest Financial update
In its latest quarterly report, released on 6/30/2024, the company reported earnings of -1.22 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.22 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -173.05% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -3.70% during the next five years compared to 5.58% growth over the previous five years of trading.
Beam Therapeutics Inc (NASDAQ: BEAM) Trading Performance Indicators
Here are Beam Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.27.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.80, a number that is poised to hit -1.19 in the next quarter and is forecasted to reach -4.66 in one year’s time.
Technical Analysis of Beam Therapeutics Inc (BEAM)
Beam Therapeutics Inc (NASDAQ: BEAM) saw its 5-day average volume 0.86 million, a negative change from its year-to-date volume of 1.34 million. As of the previous 9 days, the stock’s Stochastic %D was 80.29%. Additionally, its Average True Range was 1.62.
During the past 100 days, Beam Therapeutics Inc’s (BEAM) raw stochastic average was set at 45.06%, which indicates a significant decrease from 98.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 60.93% in the past 14 days, which was lower than the 61.44% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $25.80, while its 200-day Moving Average is $27.46. Nevertheless, the first resistance level for the watch stands at $27.69 in the near term. At $28.56, the stock is likely to face the second major resistance level. The third major resistance level sits at $30.27. If the price goes on to break the first support level at $25.11, it is likely to go to the next support level at $23.40. The third support level lies at $22.53 if the price breaches the second support level.
Beam Therapeutics Inc (NASDAQ: BEAM) Key Stats
With a market capitalization of 2.21 billion, the company has a total of 82,311K Shares Outstanding. Currently, annual sales are 377,710 K while annual income is -132,530 K. The company’s previous quarter sales were 11,770 K while its latest quarter income was -91,050 K.
